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Abstract
Elevated levels of cytokines/chemokines contribute to increased neuroinvasion of human immunodeficiency virus
type 1 (HIV-1). Previous work showed that lipopolysaccharide (LPS), which is present in the plasma of patients with
HIV-1, enhanced transcellular transport of HIV-1 across the blood-brain barrier (BBB) through the activation of p38
mitogen-activated protein kinase (MAPK) signaling in brain microvascular endothelial cells (BMECs). Here, we found
that LPS (100 μg/mL, 4 hr) selectively increased interleukin (IL)-6 and granulocyte-macrophage colony-stimulating
factor (GM-CSF) release from BMECs. The enhancement of HIV-1 transport induced by luminal LPS was neutralized
by treatment with luminal, but not with abluminal, antibodies to IL-6 and GM-CSF without affecting paracellular
permeability as measured by transendothelial electrical resistance (TEER). Luminal, but not abluminal, IL-6 or GM-
CSF also increased HIV-1 transport. U0126 (MAPK kinase (MEK)1/2 inhibitor) and SB203580 (p38 MAPK inhibitor)
decreased the LPS-enhanced release of IL-6 and GM-CSF. These results show that p44/42 and p38 MAPK signaling
pathways mediate the LPS-enhanced release of IL-6 and GM-CSF. These cytokines, in turn, act at the luminal
surface of the BMEC to enhance the transcellular transport of HIV-1 independently of actions on paracellular
permeability.
Keywords: Blood-brain barrier, Human immunodeficiency virus type 1, Lipopolysaccharide, Interleukin-6, Granulo-
cyte-macrophage colony-stimulating factor, Mitogen-activated protein kinase
Background
Human immunodeficiency virus type 1 (HIV-1) infec-
tion induces neurological dysfunctions known as the
AIDS-dementia complex or HIV-associated dementia
(HAD). Although highly active antiretroviral therapy
(HAART) and combination antiretroviral therapy
(cART) have dramatically decreased the incidence and
severity of HAD, the prevalence of HAD, including
minor cognitive and motor disorders, is increasing with
the longer lifespan of HIV patients [1]. Most antiretro-
viral drugs comprising HAART have a restricted entry
into the brain because of blood-brain barrier (BBB)
efflux transporters so that the brain serves as a reservoir
for HIV-1 [2] and a source for viral escape [3]. There-
fore, HIV-1 in the brain can contribute to the incidence
and development of HIV-associated neurological impair-
ment in HIV-1 patients both prior to and after treat-
ment with HAART/cART.
HIV-1 can enter the brain by two routes: the passage
of cell-free virus by an adsorptive endocytosis-like
mechanism [4-7] and trafficking of HIV-1-infected
immune cells across the BBB [8]. HIV-1 infection of
brain endothelial cells (BECs) is not a productive infec-
tion [9] and penetration of HIV-1 is independent of the
CD4 receptor [10]. At the early stage, HIV-1 enters the
brain through an intact, normally functioning BBB [11].
At later stages of infection, elevated levels of proinflam-
matory cytokines/chemokines in the blood of patients
with AIDS [12-14] are likely associated with the increase
in HIV-1 infiltration [15-17], while HIV-1 gp120 and
Tat induce the disruption of tight junctions in BECs
[17-20].
As reported by Brenchley et al. and confirmed by
others, plasma levels of lipopolysaccharide (LPS), a
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any medium, provided the original work is properly cited.Gram-negative bacterial endotoxin, are higher in chronic
HIV-infected patients with HAART than in the unin-
fected [3,21]. Bacterial infection in HIV patients influ-
ences the severity and rate of disease progression [22].
Peripheral LPS induces various inflammatory and immu-
nological reactions including the production of cyto-
kines/chemokines, such as tumor necrosis factor-a
(TNF-ainterleukin (IL)-1, and IL-6 [23-25]. TNF-a
enhances HIV-1 transport across the BBB [15] and LPS
induces an increase in HIV-1-infected monocyte trans-
port across the BBB [8]. In our previous in vivo study,
we found that the peripheral injection of LPS enhanced
gp120 uptake by brain [26]. These studies suggest that
elevated levels of inflammatory mediators, including
cytokines/chemokines and LPS, regulate the permeabil-
ity of the BBB to HIV-1. BECs express LPS receptors,
such as Toll-like receptor (TLR)-2, TLR-4, and CD14
[27] and are targets of LPS. The barrier function of the
BBB is affected by various cytokines/chemokines in the
blood compartment [28]. Several studies using in vitro
BBB models have shown that LPS increases the paracel-
lular permeability of the BBB [29-33]. LPS induces or
enhances the secretion of several cytokines by BECs
[34]. Thus, bacterial infection and the accompanying
inflammatory state could be involved in the enhance-
ment of HIV-1 entry into the brain.
We recently reported that LPS increased transcellular
transport of HIV-1 across the BBB through p38 mito-
gen-activated protein kinase (MAPK) [35]. Here, we
examined whether LPS-enhanced release of cytokines by
BMECs mediated the transcellular transport of HIV-1
and was regulated by MAPK signaling pathways.
Materials and methods
Radioactive labeling
HIV-1 (MN) CL4/CEMX174 (T1) prepared and ren-
dered noninfective by aldrithiol-2 treatment as pre-
viously described [36] was a kind gift of the National
Cancer Institute, NIH. The virus was radioactively
labeled by the chloramine-T method, a method which
preserves vial coat glycoprotein activity [37,38]. Two
mCi of
131I-Na (Perkin Elmer, Boston, MA), 10 μgo f
chloramine-T (Sigma) and 5.0 μg of the virus were incu-
bated together for 60 sec. The radioactively labeled virus
was purified on a column of Sephadex G-10 (Sigma).
Primary culture of mouse brain microvascular endothelial
cells (BMECs)
BMECs were isolated by a modified method of Szabó et
al. [39] and Nakagawa et al. [38]. The animals were
housed in clean cages in the laboratory with free access
to food and water and were maintained on a 12-h dark,
12-h light cycle in a room with controlled temperature
(24 ± 1°C) and humidity (55 ± 5%). All procedures
involving experimental animals were approved by the
local Animal Care and Use Committee and were per-
formed in a facility approved by Association for Assess-
ment and Accreditation of Laboratory Animal Care.
Cerebral cortices harvested from 8-week-old male CD-1
mice from our in-house colony were homogenized,
BMECs extracted, and cultured as previously performed
[40]. Cultures were treated with puromycin to remove
pericytes.
Preparation of in vitro BBB models
BMECs (4 × 10
4 cells/well) were seeded on the inside of
the fibronectin-collagen IV (0.1 and 0.5 mg/mL, respec-
tively)-coated polyester membrane (0.33 cm
2,0 . 4μm
pore size) of a Transwell
®-Clear insert (Costar, Corning,
NY) placed in the well of a 24-well culture plate
(Costar). Culture methods were the same as previously
reported [35]. Transendothelial electrical resistance
(TEER in Ω ×c m
2) was measured before the experi-
ments and after an exposure of LPS using an EVOM
voltohmmeter equipped with STX-2 electrode (World
Precision Instruments, Sarasota, FL). The TEER of cell-
free Transwell
®-Clear inserts were subtracted from the
obtained values.
Pretreatment protocol
Lipopolysaccharide from Salmonella typhimurium (LPS;
Sigma), monoclonal anti-mouse GM-CSF antibody, anti-
mouse IL-6 antibody, mouse GM-CSF, and mouse IL-6
(all purchased from R&D systems, Minneapolis, MN)
were dissolved in serum-free DMEM/F-12 (DMEM/F-12
containing 1 ng/mL bFGF and 500 nM hydrocortisone).
The dose of LPS used in previous BMEC studies (100
μg/mL) was added to the luminal chamber of the Trans-
well
® inserts, and anti-mouse GM-CSF antibody (10 μg/
mL), anti-mouse IL-6 antibody (10 μg/mL), mouse GM-
CSF (1-100 ng/mL), or mouse IL-6 (1-100 ng/mL) was
loaded into the luminal or abluminal chamber. Then,
the BMEC monolayers were incubated for 4 hr at 37°C
with a humidified atmosphere of 5% CO2/95% air. In
the experiments using antibodies, rat IgG (Sigma) was
added to the control and LPS-treated group (10 μg/mL
as final concentration).
U0126 (MEK inhibitor; Tocris Cookson Inc., Ellisville,
MO), SB203850 (p38 MAPK inhibitor; Tocris) and
SP600125 (Jun kinase (JNK) inhibitor; Sigma) were first
dissolved in dimethyl sulfoxide (DMSO) and diluted
with serum-free DMEM/F-12 (0.1% as the final DMSO
concentration).
Transendothelial transport of
131I-HIV-1
For the transport experiments, the medium was
removed and BMECs were washed with physiological
buffer containing 1% BSA (141 mM NaCl, 4.0 mM KCl,
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mM HEPES, 10 mM D-glucose and 1% BSA, pH 7.4).
The physiological buffer containing 1% BSA was added
to the outside (abluminal chamber; 0.6 mL) of the
Transwell
® insert. To initiate the transport experiments,
131I-HIV-1 (3 × 10
6 cpm/mL) was loaded on the luminal
chamber. The side opposite to that to which the radio-
active materials were loaded is the collecting chamber.
Samples (0.5 ml) were removed from the abluminal
chamber at 15, 30, 60 and 90 min and immediately
replaced with an equal volume of fresh 1% BSA/physio-
logical buffer. All samples were mixed with 30% tri-
chloroacetic acid (TCA; final concentration 15%) and
centrifuged at 5, 400 ×g for 15 min at 4°C. Radioactivity
in the TCA precipitate was determined in a gamma
counter. The permeability coefficient and clearance of
TCA-precipitable 131I-HIV-1 was calculated according
to the method described by Dehouck et al. [41]. Clear-
ance was expressed as microliters (μL) of radioactive
tracer diffusing from the luminal to abluminal (influx)
chamber and was calculated from the initial level of
radioactivity in the loading chamber and final level of
radioactivity in the collecting chamber:
Clearance(µL) =[ C ] C × VC/[C]L,
where [C]L is the initial radioactivity in a microliter of
loading chamber (in cpm/μL), [C]C is the radioactivity
in a microliter of collecting chamber (in cpm/μL), and
VC is the volume of collecting chamber (in μL). During
a 90-min period of the experiment, the clearance
volume increased linearly with time. The volume cleared
was plotted versus time, and the slope was estimated by
linear regression analysis. The slope of clearance curves
for the BMEC monolayer plus Transwell
® membrane
was denoted by PSapp,w h e r ePS is the permeability ×
surface area product (in μL/min). The slope of the clear-
ance curve with a Transwell
® membrane without
BMECs was denoted by PSmembrane.T h er e a lPS value
for the BMEC monolayer (PSe) was calculated from
1/PSapp =1 / PSmembrane +1 / PSe.
The PSe values were divided by the surface area of the
Transwell
® inserts (0.33 cm
2) to generate the endothelial
permeability coefficient (Pe, in cm/min).
Cytokine detection
BMECs (4 × 10
4 cells/well) were seeded on the fibronec-
tin/collagen I/collagen IV (0.05, 0.05, and 0.1 mg/mL,
respectively)-coated 24-well culture plate (Costar).
BMECs were washed with serum-free DMEM/F-12, and
then exposed to 200 μL of LPS (100 μg/mL) with or
without U0126 (10 μM), SB203580 (10 μM), and
SP600125 (10 μM) for 4 hr at 37°C. Culture supernatant
was collected and stored at -80°C until use. The cyto-
kines (GM-CSF, IFN-g,I L - 1 a,I L - 1 b,I L - 2 ,I L - 4 ,I L - 6 ,
IL-10, IL-12 (p70), and TNF-a) were measured with the
mouse cytokine/chemokine Lincoplex
® kit (Linco
Research, St. Charles, MO) by following the manufac-
turer’s instructions.
Western blot analysis
LPS, GM-CSF, or IL-6-treated and control BMECs were
washed three times with ice-cold phosphate buffered
saline containing 1 mM sodium orthovanadate
(Na3VO4) and 1 mM sodium fluoride (NaF). Cells were
scraped and lysed in phosphoprotein lysis buffer (10
m MT r i s - H C l ,p H6 . 8 ,1 0 0m MN a C l ,1m ME D T A ,1
mM EGTA, 10% glycerol, 1% Triton X-100, 0.1% SDS,
0.5% sodium deoxycholate, 20 mM sodium pyropho-
sphate decahydrate, 2 mM Na3VO4,1m MN a F ,1m M
phenylmethylsulfonyl fluoride) containing 1% protease
inhibitor cocktail (Sigma) on ice. Cell lysates were cen-
trifuged (15, 000 ×g at 4°C for 15 min) and the superna-
tants were stored at -80°C until use. The protein
concentration of each sample was determined using a
BCA protein assay kit (Pierce, Rockford, IL). Twenty to
thirty μg of the total protein was mixed with NuPAGE
®
LDS sample buffer (Invitrogen) and incubated for 3 min
at 100°C. Proteins were separated on NuPAGE
® Novex
4-12% Bis-Tris gel (Invitrogen) and then transferred to a
polyvinylidene difluoride (PVDF) membrane (Invitro-
gen). After transfer, the blots were blocked with 5%
BSA/Tris-buffered saline (TBS: 20 mM Tris-HCl, pH
7.5, 150 mM NaCl) containing 0.05% Tween 20 (TBS-T)
for 1 hr at room temperature. The membrane was incu-
bated with the primary antibody diluted in 5% BSA/
TBS-T overnight at 4°C. The phosphorylation of p44/42
MAPK, p38 MAPK and JNK were detected using anti-
phospho-p44/42 MAPK (1:1000), anti-phospho-p38
MAPK (1:500) and anti-phospho-JNK (1:500) rabbit
monoclonal antibodies, respectively (all purchased from
Cell Signaling Technology, Beverly, MA). Occludin,
claudin-5, and ZO-1 were detected using anti-occludin,
anti-claudin-5, and anti-ZO-1 mouse monoclonal anti-
bodies (all purchased from Zymed, South San Francisco,
CA). Blots were washed and incubated with horseradish
peroxidase-conjugated anti-mouse IgG or anti-rabbit
IgG (1:10, 000; Santa Cruz Biotechnology, Santa Cruz,
CA) diluted in 5% BSA/TBS-T for 1 hr at room tem-
perature. The immunoreactive bands were visualized on
an X-ray film (Kodak) using SuperSignal
® West Pico
chemiluminescent substrate kit (Pierce). To reprobe
total p44/42 MAPK, p38 MAPK, JNK, and actin, the
membrane was incubated in stripping buffer (0.2 M gly-
cine, 0.1% SDS and 1% Tween 20, pH 2.2) for 15 min
twice and blocked with 5% non-fat dry milk/TBS-T. The
total p44/42 MAPK, p38 MAPK and JNK were detected
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JNK (1:1000) (all purchased from Cell Signaling Tech-
nology), and actin (1:1000; Santa Cruz Biotechnology)
antibodies, respectively. To quantify the relative levels of
protein expression, the intensity of specific protein
bands was quantified using ImageJ software (National
Institute of Health, Bethesda, MD) and then normalized
by that of each loading control protein.
Statistical analysis
Values are expressed as means ± SEM. One-way and
two-way analysis of variances (ANOVAs) followed by
Dunnett’s or Tukey-Kramer’s test were applied to multi-
ple comparisons. Paired t-test was applied to the densi-
tometry analysis. The differences between means were
considered to be significant when P values were less
than 0.05 using Prism 5.0 (GraphPad, San Diego, CA).
Results
LPS stimulated release of GM-CSF and IL-6 by BMEC
As shown in Table 1, BMECs spontaneously secreted
IL-1b, IL-2, IL-4, IL-10, IL-12, and TNF-a in the 0.5-2.5
p g / m Lr a n g e ,a n dG M - C S F ,I F N - g,a n dI L - 6i n4 - 7p g /
mL range in this study. The concentration of IL-1a was
below the detection level of the assay. A 4 hr exposure
of BMECs to LPS (100 μg/mL) significantly induced 33-
and 2.4-fold increases in the levels of GM-CSF and IL-6,
respectively (P < 0.01). LPS significantly decreased the
secretion of IFN-g by BMECs (P <0 . 0 1 ) ,b u tt h e
decrease in the secretion of IL-12 with LPS did not
reach statistical significance. Secretion of IL-1b,I L - 2 ,
and IL-10 was not detected after LPS treatment. The
l e v e lo fI L - 4a n dT N F - a did not change after LPS
treatment.
Polarized effect of antibodies to IL-6 and GM-CSF on LPS-
induced increase in HIV-1 permeability and paracellular
permeability of BMEC monolayer
To examine whether the enhanced release of IL-6 and
GM-CSF induced by LPS was involved in the LPS-
induced increases in HIV-1 permeability and paracellu-
lar permeability of the BMEC monolayer, we exposed
BMEC monolayers to LPS with antibodies to IL-6 and
GM-CSF. Since BMECs can release cytokines from
either their luminal or abluminal surface [34], we exam-
ined the functional polarity of antibodies to IL-6 and
GM-CSF by adding them into the luminal or abluminal
chambers. We assessed the paracellular permeability of
the BMEC monolayer by measuring TEER. LPS (100 μg/
mL for 4 hr) added to the luminal chamber significantly
increased
131I-HIV-1 permeability of BMEC monolayers
(Figure 1A and 1C) and decreased TEER (Figure 1B and
1D). The presence of antibodies to IL-6 and GM-CSF
(10 μg/mL, respectively) in the luminal chamber signifi-
cantly attenuated the LPS-induced increase in
131I-HIV-
1 (Figure 1A), but not the LPS-induced decrease in
TEER (Figure 1B). In contrast, antibodies added into the
abluminal chamber did not inhibit the LPS-induced
increase in
131I-HIV-1 permeability and the decrease in
TEER (Figure 1C and 1D).
Polarized response to IL-6 and GM-CSF in the
permeability of BMEC monolayer
To determine whether IL-6 and GM-CSF mediate HIV-1
transport across the BBB and decrease TEER with the
functional polarity, BMECs were treated with various
concentrations of mouse IL-6 and GM-CSF (1-100 ng/
mL, respectively) in the luminal or abluminal chamber.
In Figure 2A, luminal treatment with IL-6 (1, 10, and 100
ng/mL) increased HIV-1 transport to 104.6 ± 6.8, 121.9 ±
5.4, and 127.9 ± 4.1% of control, but abluminal treatment
did not induce significant changes in HIV-1 transport
(96.5 ± 3.2, 110.2 ± 3.6, and 99.6 ± 5.0% of control).
Luminal treatment with IL-6 (1, 10, and 100 ng/mL) sig-
nificantly decreased TEER (Figure 2B) from 72.1 ± 1.2 to
64.2 ± 2.8, 58.3 ± 2.0, and 56.4 ± 1.4 Ω ×c m
2. Abluminal
treatment with IL-6 significantly decreased TEER from
72.0 ± 2.0 to 58.9 ± 2.7 Ω ×c m
2 at the concentration of
100 ng/mL. For the permeability to HIV-1 (Figure 2A), a
two-way ANOVA showed significant effects for the fac-
tors “loading chamber” (luminal or abluminal) [F(1, 67) =
11.42, P < 0.01], concentration [F(3, 67) = 5.715, P <
0.01], and interaction (loading chamber × concentration)
[F(3, 67) = 2.788, P < 0.05]. For TEER (Figure 2B), a two-
way ANOVA showed a significant effect for concentra-
tion [F(3, 58) = 10.08, P < 0.001], but not for loading
chamber and interaction.
As shown in Figure 3A, GM-CSF (1, 10, 100 ng/mL)
in the luminal chamber increased HIV-1 transport to
Table 1 Effect of LPS on the release of cytokines by
BMECs.
Treatment
Cytokine (pg/mL) Control LPS 100 μg/mL
GM-CSF 4.8 ± 3.1 160.0 ± 21.7**
IFN-g 4.4 ± 1.1 1.6 ± 0.6*
IL-1a N.D. N.D.
IL-1b N.D. N.D.
IL-2 1.1 ± 0.5 N.D.
IL-4 0.9 ± 0.2 0.5 ± 0.2
IL-6 6.7 ± 1.1 16.3 ± 2.3**
IL-10 2.3 ± 1.1 N.D.
IL-12 (p70) 1.6 ± 0.6 0.3 ± 0.3
TNF-a 0.5 ± 0.3 0.2 ± 0.2
BMECs were exposed to LPS (100 μg/mL) for 4 hr. Mean ± SEM (n = 7). N.D.:
Not Detected. Statistical analysis was done by Student’s t-test. * P < 0.05, ** P
< 0.01 vs control.
Dohgu et al. Journal of Neuroinflammation 2011, 8:167
http://www.jneuroinflammation.com/content/8/1/167
Page 4 of 12103.6 ± 3.4, 107.0 ± 5.4, and 124.0 ± 5.1% of control, but
GM-CSF in the abluminal chamber did not (101.8 ± 5.1,
94.5 ± 3.9, and 95.4 ± 5.2% of control). Neither the lumi-
nal nor abluminal treatments with GM-CSF changed
TEER (Figure 3B). For the permeability to HIV-1 (Figure
3A), a two-way ANOVA showed significant effects for
loading chamber [F(1, 44) = 7.746, P < 0.01] and interac-
tion [F(3, 44) = 2.909, P < 0.01] but not concentration.
For TEER (Figure 3B), a two-way ANOVA showed a sig-
nificant effect for loading chamber [F(1, 74) = 4.682, P <
0.05] but not concentration or interaction.
These results indicated that the effects of LPS on
BMECs permeability to HIV-1 were mainly mediated by
IL-6 and GM-CSF acting at the luminal surface of the
BMEC. In all subsequent studies, therefore, we
employed the luminal chamber as the loading chamber.
Figure 1 Effects of antibodies to IL-6 and GM-CSF on LPS-induced changes in the permeability of BMECs to
131I-HIV-1 (A and C) and
TEER (B and D). LPS (100 μg/mL) was added to the luminal chamber. In panels A and B, antibodies to IL-6 or GM-CSF were added to the
luminal chamber. In panels C and D, antibodies to IL-6 or GM-CSF were added to the abluminal chamber. After 4 hr of incubation, transport
study was performed. In panels A and C, results are expressed as % of control. Control values were 1.52 ± 0.16 × 10
-5 and 1.52 ± 0.05 × 10
-5
cm/min (A and C, respectively). Values are means ± SEM (n = 9-15). *P < 0.05, ***P < 0.001, significant differences from control.
#P < 0.05,
##P <
0.01, significant differences from LPS (100 μg/mL).
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tight junction proteins
To examine the effects of LPS, IL-6, and GM-CSF on
the expression of tight junction proteins, BMECs were
exposed to LPS (100 μg/mL), IL-6 (100 ng/mL), and
GM-CSF (100 ng/mL) for 4 hr (Figure 4). The densito-
metry analysis showed that there were no significant
changes in the expression of tight junction proteins
induced by LPS, IL-6, and GM-CSF.
Effect of MAPK inhibitors on the release of IL-6 and GM-
CSF enhanced by LPS
We previously demonstrated that LPS activated p44/42
MAPK and p38 MAPK pathways in BMECs [35]. To
test whether LPS enhances the release of IL-6 and GM-
CSF by BMECs through MAPK signaling pathways,
BMECs were exposed to LPS with various MAPK inhi-
bitors (U0126, SB203580, and SP600125) for 4 hr. As
shown in Figure 5A and 5B, LPS significantly enhanced
the release of IL-6 and GM-CSF by BMECs from 1.7 ±
0.71 to 35.5 ± 10.5 pg/mL (P < 0.01) and from 7.8 ± 7.8
to 261.4 ± 25.7 pg/mL (P < 0.001), respectively. In the
presence of 10 μM of U0126 (MEK1/2 inhibitor), the
LPS-induced increase in the release of IL-6 and GM-
CSF by BMECs was significantly decreased to 13.0 ± 2.1
(P < 0.05 vs LPS) and 199.0 ± 16.0 pg/mL (P <0 . 0 5v s
LPS), respectively. Similarly, SB203580 (10 μM: p38
MAPK inhibitor) significantly decreased the LPS-
enhanced release of IL-6 and GM-CSF by BMECs to
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Figure 2 Functional polarity to IL-6 in BMEC permeability of
HIV-1 (A) and TEER (B). BMECs were exposed to IL-6 (1, 10, and
100 ng/mL) in the luminal or abluminal chamber for 4 hr. In panel
A, results are expressed as % of control. The control values of
permeability coefficient for
131I-HIV-1 in panel A was 1.03 ± 0.11 ×
10
-5 and 1.07 ± 0.08 × 10
-5 cm/min for the luminal and abluminal
control, respectively. Values are means ± SEM (n = 3-12). *P < 0.05,
**P < 0.01, ***P < 0.001, significant difference from each
corresponding control.
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Figure 3 Functional polarity to GM-CSF in BMEC permeability
of HIV-1 (A) and TEER (B). BMECs were exposed to GM-CSF (1, 10,
and 100 ng/mL) in the luminal or abluminal chamber for 4 hr. In
panel A, results are expressed as % of control. The control values of
permeability coefficient for
131I-HIV-1 in panel A was 137 ± 0.13 ×
10
-5 and 1.32 ± 0.13 × 10
-5 cm/min for the luminal and abluminal
control, respectively. Values are means ± SEM (n = 3-12). **P < 0.01,
significant difference from control.
Dohgu et al. Journal of Neuroinflammation 2011, 8:167
http://www.jneuroinflammation.com/content/8/1/167
Page 6 of 1214.9 ± 3.1 (P < 0.05 vs LPS) and 139.9 ± 10.8 pg/mL (P
< 0.01 vs LPS). The JNK inhibitor SP600125 (10 μM)
did not affect the LPS-enhanced release of IL-6 and
GM-CSF.
Effects of IL-6 and GM-CSF on phosphorylation of p44/42
MAPK, p38, and JNK
To determine whether IL-6 and GM-CSF could activate
MAPK pathways in BMECs as in the case of LPS phos-
phorylation of MAPKs were measured by western blot
analysis (Figure 6). A 4 hr exposure of BMECs to IL-6
(100 ng/mL) or GM-CSF (100 ng/mL) in the luminal
side did not increase the phosphorylation of p44/42
MAPK, p38, or JNK.
Discussion
The present study evaluated whether the LPS-enhanced
transcellular transport of HIV-1 across BMEC mono-
layers was mediated through the induction of the release
of cytokines from BMECs. Our main findings are sum-
marized in Figure 7. BMECs spontaneously secreted
GM-CSF, IFN-g,I L - 2 ,I L - 4 ,I L - 6 ,a n dT N F - a (Table 1)
with relatively high concentrations (> 4 pg/mL) of IL-6,
GM-CSF, and IFN-g. LPS markedly increased the con-
centrations of IL-6 and GM-CSF. Therefore, we
hypothesized that IL-6 and/or GM-CSF might mediate
the LPS-induced increase in HIV-1 transport across the
BBB. Previously, we showed that BMECs in which peri-
cytes were not removed spontaneously secrete GM-CSF,
IL-1a,I L - 6 ,I L - 1 0 ,a n dT N F - a and that LPS stimulates
the secretion of GM-CSF, IL-6, IL-10, and TNF-a [34].
In the current study, the LPS-induced increase in IL-10
and TNF-a secretion was not observed. This may be
attributed to the differences of culture conditions, such
as the use of culture medium containing hydrocortisone,
absence of pericytes, or differences among batches of
LPS. Although hydrocortisone inhibits the production of
TNF-a by LPS-stimulated monocytes [42], the
Figure 4 Effects of LPS, IL-6, and GM-CSF on the expression of tight junction proteins in BMECs. BMECs were exposed to LPS (100 μg/
mL), IL-6 (100 ng/mL), or GM-CSF (100 ng/mL) for 4 hr. Expression levels of occludin, claudin-5, ZO-1, and actin were detected by western blot.
Relative intensity of occludin (A), claudin-5 (B), and ZO-1 (C) is calculated as ratio of arbitrary densitometric units of target protein to that of
actin. Results are expressed % of control. Values are means ± SEM (n = 3). (D) Photographs are representative in three independent experiments.
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Page 7 of 12concentration of hydrocortisone that we used was at a
physiological level [43].
BBB disruption can occur either [44] through the
paracellular route (increased leakage between cells as
measured by a decrease in TEER) or though the trans-
cellular route (increased passage across a cell). Viral-
sized particles [45], including HIV-1 [7], generally cross
by the transcellular route. Our previous work found that
LPS both increased the transcellular permeability of the
BMEC monolayer to HIV-1 and decreased TEER [35].
Here, we examined whether IL-6 and GM-CSF release
from BMEC by LPS mediated these effects. The pre-
sence of LPS and antibodies to IL-6 or GM-CSF in the
luminal chamber attenuated LPS-enhanced HIV-1 trans-
port across the BMEC monolayer without a change in
TEER (Figure 1A and 1B). BMECs secrete IL-6 and
GM-CSF into both the luminal and abluminal chambers
[34]. To determine whether IL-6 and GM-CSF secreted
by BMECs into the abluminal chamber are also involved
Figure 5 Effects of various MAPK inhibitors on LPS-enhanced
release of IL-6 (A) and GM-CSF (B) by BMECs. BMECs were
treated with LPS (100 μg/mL) for 4 hr in the presence or absence of
U0126 (10 μM), SB203580 (10 μM), or SP600125 (10 μM). Values are
means ± SEM (n = 5-8). **P < 0.01, significant differences from
control.
#P < 0.05,
##P < 0.01, significant differences from LPS (100
μg/mL).
Figure 6 Effects of IL-6 and GM-CSF on phosphorylation of
MAPKs in BMECs. BMECs were exposed to IL-6 (100 ng/mL) or
GM-CSF (100 ng/mL) for 4 hr. Western blot analyses were
performed to detect phosphorylated p44/42 MAPK (A), p38 MAPK
(B), and JNK (C) as well as total p44/42 MAPK, p38 MAPK, and JNK.
Relative intensity is calculated as ratio of arbitrary densitometric
units of phoshorylated protein to that of total protein. (C) For
phospho-JNK, sorbitol-treated PC12 cells were used as positive
control (data not shown). Results are expressed % of control. Values
are means ± SEM (n = 3-4). Photographs are representative in three
to four independent experiments.
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Page 8 of 12in the LPS-induced increase in HIV-1 transport, we
added antibodies to IL-6 or GM-CSF to the abluminal
chamber. Neither antibody in the abluminal chamber
inhibited the luminal LPS-induced changes in HIV-1
transport and TEER (Figure 1C and 1D). These results
show that the IL-6 and GM-CSF secreted by BMECs in
response to luminal exposure to LPS act at the luminal,
but not the abluminal, endothelial surface to increase
the transcellular permeability of BMECs to HIV-1.
Furthermore, the results suggest that the LPS-induced
increase in the paracellular permeability of the BMEC
monolayer as measured by TEER is not mediated by
extracellular IL-6 and GM-CSF.
We further investigated this functional polarity by
adding IL-6 and GM-CSF to the luminal or abluminal
chamber. Polarity of other cytokine actions has been
investigated. We previously found that BMECs show no
functional polarity in the reduction of paracellular per-
meability by transforming growth factor (TGF)-b1 [46].
That is, either luminal or abluminal TGF-b1h a st h e
same effect on the BBB paracellular permeability. In
contrast, MCP-1 is only able to stimulate monocyte
migration across BMECs when added to the abluminal
surface [47]. In the current study, only luminal IL-6
increased HIV-1 transport and was 10-100 fold more
potent than abluminal IL-6 in decreasing TEER (Figure
2). Consistent with this, de Vries et al. reported that IL-
6 increased paracellular permeability of BMECs [48].
However, we found here that the IL-6-induced decrease
in TEER was less than the LPS-induced decrease in
TEER. Other soluble factors, such as other cytokines or
chemokines, may be responsible for the remaining
L LPS 
IL-6 GM-CSF 
IL-6 
GM-CSF 
HIV-1 
TIGHT 
JUNCTION 
PROTEINS  L 6 GM
I
LUMINAL 
ABLUMINAL 
Figure 7 Schematic of findings. LPS released both GM-CSF and IL-6 through MAPKs p44/42 and p38 pathways. Previous work has shown that
LPS-induced tight junction disruption (paracellular permeability) is mediated through the p44/42 MAPK pathway whereas HIV-1 transcytosis is
mediated through the p38 MAPK pathway. Tight junction function as measured by TEER but not tight junction protein expression as measured
by western blots was influenced by IL-6 (but not GM-CSF) through a site not blocked by antibodies and so assumed to be intracellular. GM-CSF
and IL-6 both promoted HIV-1 transcytosis. The transcytotic effects of GM-CSF and IL-6 were mediated through luminal but not abluminal sites
that were blocked by antibodies and therefore assumed to be extracellular.
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Page 9 of 12increase in the paracellular permeability induced by LPS.
An IL-6-independent, P44/42-mediated phosphorylation
of tight junction proteins may also be operational. The
ability of IL-6 to decrease TEER but an inability of IL-6
antibody to block the effect of LPS on TEER suggests
either that the LPS effect is not mediated through IL-6
or that IL-6 acts at a site not available to antibodies,
such as inside the cell. Abluminal IL-6 (100 ng/mL) did
not alter HIV-1 permeability despite the decrease in
TEER. This finding is consistent with IL-6 promoting a
transcellular or transcytotic mechanism for HIV-1 pas-
sage across the BBB that is independent of the paracel-
lular pathway.
Luminal GM-CSF at the concentration of 100 ng/mL
increased HIV-1 transport, whereas abluminal GM-CSF
did not. Neither luminal nor abluminal GM-CSF chan-
ged TEER (Figure 3). This result further supports the
idea that HIV-1 penetration across the BBB is through
the transcellular route rather than the paracellular route.
In addition, these results may suggest that the receptors
for IL-6 and GM-CSF that affect HIV-1 permeability are
mainly localized to the luminal membrane of BMECs.
Therefore, enhanced invasion of HIV-1 into the brain
may be mediated by BMEC-derived cytokines secreted
into blood or by blood-borne cytokines. Consistent with
this, IL-6 in the blood compartment induces BBB dys-
function [48,49]. As summarized above, LPS, IL-6, and
GM-CSF altered both HIV-1 permeability and TEER.
The disparities discussed above between these two para-
meters of BBB function make it likely that they are
separate events. Whereas the increased permeability to
HIV-1 is likely mediated through transcytotic mechan-
isms, the decrease in TEER is caused by increased para-
cellular permeability resulting from altered tight
junction function. LPS is known to alter the intensity
and pattern of immunohistochemistry for the tight junc-
tion proteins claudin-5, ZO-1, and F-actin in BMECs
[31,33]. We examined whether LPS, IL-6, and GM-CSF
affected the expression of these tight junction proteins
in our models (Figure 4). The luminal treatment with
L P S ,I L - 6 ,o rG M - C S Fd i dn o ti n d u c es i g n i f i c a n t
changes in the expression of tight junction proteins in
BMECs. Therefore, under the conditions of our model,
LPS and IL-6 are likely increasing paracellular perme-
ability of BMECs by altering tight junction function
rather than expression of their proteins. For example,
LPS and IL-6 may affect the localization of tight junc-
tion proteins in BMECs to increase the paracellular
permeability.
Our previous work showed that LPS activated p44/42
MAPK and p38 MAPK in BMECs, and the activation of
p38 MAPK resulted in the increase in HIV-1 transport
[35]. The activation of the p38 MAPK pathway leads to
the production and release of inflammatory cytokines
[50]. Considering our present results, we hypothesized
that either (i) LPS induced the production of IL-6 and
GM-CSF through MAPKs or (ii) IL-6 and GM-CSF acti-
vated MAPKs. First, we determined whether the LPS-
enhanced release of IL-6 and GM-CSF was mediated by
MAPK signaling pathways as shown by the experiments
using U0126 (MEK1/2 inhibitor), SB203580 (p38 MAPK
inhibitor), and SP600125 (JNK inhibitor) (Figure 5).
U0126 and SB203580 inhibited the LPS-enhanced
release of IL-6 and GM-CSF by BMECs. In the
SP600125-treated group, inhibitory effects were not
detected. This is reasonable as an LPS-induced increase
in the phosphorylation of JNK has not been detected
[35]. These results indicated that LPS enhanced the
release of IL-6 and GM-CSF from BMECs through the
phosphorylation of p44/42 MAPK and p38 MAPK.
Thus, the transcellular pathway taken by free virus dif-
fers from the JNK dependent, CD40-mediated pathway
used by infected monocytes to cross the BBB [3].
Next, we determined whether IL-6 and GM-CSF
increased the phosphorylation of MAPKs. IL-6 and GM-
CSF did not increase the phosphorylation of p44/42
MAPK, p38 MAPK, or JNK (Figure 6). These results
indicated that the IL-6- and GM-CSF-induced changes
in the BMEC permeability for HIV-1 and paracellular
permeability are downstream of the MAPK signaling
pathways. Pathways downstream of the cytokines are
likely COX-2 for IL-6-induced changes in TEER [48]
and the JAK/STAT pathway for IL-6 and GM-CSF
[51,52] mediation of HIV-1 effects on immune cell
migration [53]. Thus, IL-6 and GM-CSF likely increase
HIV-1 transport across the BBB through other intracel-
lular signaling pathways. As for the mechanisms by
which LPS could increase HIV-1 transport across the
BBB, the following sequential events are proposed: (1)
LPS activates p44/42 MAPK and p38 MAPK in BMECs;
(2) this activation induces BMECs to release IL-6 and
GM-CSF into the blood; (3) IL-6 and GM-CSF act at
the luminal surface of the BMECs to enhance the trans-
cellular transport of HIV-1 across the BBB.
In our previous study, we demonstrated that p38
MAPK mediated LPS-enhanced HIV-1 transport and
p44/42 MAPK mediated the LPS-induced increase in
paracellular permeability using each pathway inhibitor
[35]. U0126, the p44/42 MAPK inhibitor, did not
attenuate LPS-enhanced HIV-1 transport. Here, U0126
as well as SB203580 decreased the release of IL-6 and
GM-CSF (Figure 5). These findings suggest that the p38
MAPK signaling pathway directly leads to enhanced
LPS-mediated transcellular transport of HIV-1.
In conclusion, we found that LPS potentiated the
release of IL-6 and GM-CSF by BMECs through the
activation of p44/42 MAPK and p38 MAPK. In addition
to the p38 MAPK pathway, IL-6 and GM-CSF released
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Page 10 of 12from BECs acted at the luminal but not the abluminal
surface to enhance HIV-1 transcellular transport. The
p44/42 MAPK pathway and IL-6 likely acted at an intra-
cellular site to increase paracellular permeability. Thus,
LPS effects on HIV-permeation and on paracellular per-
meability were mediated through different cellular path-
ways. These results suggest that the release of cytokines
by BECs plays an important role in the invasion of HIV-
1 into the central nervous system. Preventing cytokine
release by BECs through MAPK signaling pathways may
be a therapeutic target in HIV-associated neurological
dysfunction.
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